🇺🇸 AZD6094 in United States
21 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 21
Most-reported reactions
- Alanine Aminotransferase Increased — 3 reports (14.29%)
- Aspartate Aminotransferase Increased — 3 reports (14.29%)
- Pyrexia — 3 reports (14.29%)
- Acute Kidney Injury — 2 reports (9.52%)
- Anaphylactic Reaction — 2 reports (9.52%)
- Drug Hypersensitivity — 2 reports (9.52%)
- Dyspnoea — 2 reports (9.52%)
- Neutrophil Count Decreased — 2 reports (9.52%)
- Arthralgia — 1 report (4.76%)
- Blood Creatinine Increased — 1 report (4.76%)
Other Oncology approved in United States
Frequently asked questions
Is AZD6094 approved in United States?
AZD6094 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for AZD6094 in United States?
Samsung Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.